{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T08:36:37Z","timestamp":1790670997709,"version":"4.1.0"},"reference-count":25,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2009,6,1]],"date-time":"2009-06-01T00:00:00Z","timestamp":1243814400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2009,6]]},"DOI":"10.1016\/j.leukres.2008.10.004","type":"journal-article","created":{"date-parts":[[2008,11,15]],"date-time":"2008-11-15T09:42:39Z","timestamp":1226742159000},"page":"837-839","source":"Crossref","is-referenced-by-count":29,"title":["Imatinib has limited therapeutic activity for hypereosinophilic syndrome patients with unknown or negative PDGFR\u03b1 mutation status"],"prefix":"10.1016","volume":"33","author":[{"given":"Nitin","family":"Jain","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Cortes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfonso","family":"Quint\u00e1s-Cardama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taghi","family":"Manshouri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raja","family":"Luthra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillermo","family":"Garcia-Manero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hagop","family":"Kantarjian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srdan","family":"Verstovsek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"January (1)","key":"10.1016\/j.leukres.2008.10.004_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/00005792-197501000-00001","article-title":"The hypereosinophilic syndrome: analysis of fourteen cases with review of the literature","volume":"54","author":"Chusid","year":"1975","journal-title":"Medicine"},{"issue":"June (6)","key":"10.1016\/j.leukres.2008.10.004_bib2","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.7326\/0003-4819-68-6-1220","article-title":"The hypereosinophilic syndromes","volume":"68","author":"Hardy","year":"1968","journal-title":"Annals of Internal Medicine"},{"issue":"May (10)","key":"10.1016\/j.leukres.2008.10.004_bib3","doi-asserted-by":"crossref","first-page":"2759","DOI":"10.1182\/blood.V83.10.2759.2759","article-title":"The idiopathic hypereosinophilic syndrome","volume":"83","author":"Weller","year":"1994","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2008.10.004_bib4","series-title":"World health organization of tumours: tumours of haematopoietic and lymphoid tissues","article-title":"Chronic eosinophilic leukemia and the hypereosinophilic syndrome","author":"Bain","year":"2001"},{"key":"10.1016\/j.leukres.2008.10.004_bib5","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1159\/000058787","article-title":"Hypereosinophilic syndromes","volume":"76","author":"Assa\u2019ad","year":"2000","journal-title":"Chemical Immunology"},{"issue":"November (9)","key":"10.1016\/j.leukres.2008.10.004_bib6","doi-asserted-by":"crossref","first-page":"648","DOI":"10.7326\/0003-4819-121-9-199411010-00003","article-title":"Interferon-alpha treatment of six patients with the idiopathic hypereosinophilic syndrome","volume":"121","author":"Butterfield","year":"1994","journal-title":"Annals of Internal Medicine"},{"issue":"August (7)","key":"10.1016\/j.leukres.2008.10.004_bib7","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1056\/NEJMoa020150","article-title":"Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta","volume":"347","author":"Apperley","year":"2002","journal-title":"The New England Journal of Medicine"},{"issue":"March (13)","key":"10.1016\/j.leukres.2008.10.004_bib8","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1056\/NEJMoa025217","article-title":"A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome","volume":"348","author":"Cools","year":"2003","journal-title":"The New England Journal of Medicine"},{"issue":"November (9)","key":"10.1016\/j.leukres.2008.10.004_bib9","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.1182\/blood-2003-05-1627","article-title":"CHIC2 deletion, a surrogate for FIP1L1\u2013PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy","volume":"102","author":"Pardanani","year":"2003","journal-title":"Blood"},{"issue":"May (5)","key":"10.1016\/j.leukres.2008.10.004_bib10","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1038\/sj.leu.2404154","article-title":"Identification of a novel imatinib responsive KIF5B-PDGFRA fusion gene following screening for PDGFRA overexpression in patients with hypereosinophilia","volume":"20","author":"Score","year":"2006","journal-title":"Leukemia"},{"issue":"February (2)","key":"10.1016\/j.leukres.2008.10.004_bib11","doi-asserted-by":"crossref","first-page":"163","DOI":"10.3324\/haematol.10980","article-title":"Characterization of three new imatinib-responsive fusion genes in chronic myeloproliferative disorders generated by disruption of the platelet-derived growth factor receptor beta gene","volume":"92","author":"Walz","year":"2007","journal-title":"Haematologica"},{"issue":"October (1)","key":"10.1016\/j.leukres.2008.10.004_bib12","first-page":"139","article-title":"Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors","volume":"295","author":"Buchdunger","year":"2000","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"issue":"May (5)","key":"10.1016\/j.leukres.2008.10.004_bib13","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nm0596-561","article-title":"Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells","volume":"2","author":"Druker","year":"1996","journal-title":"Nature Medicine"},{"issue":"May (9317)","key":"10.1016\/j.leukres.2008.10.004_bib14","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1016\/S0140-6736(02)08505-7","article-title":"Treatment of hypereosinophilic syndrome with imatinib mesilate","volume":"359","author":"Gleich","year":"2002","journal-title":"Lancet"},{"issue":"September (9)","key":"10.1016\/j.leukres.2008.10.004_bib15","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/S0145-2126(02)00046-2","article-title":"Response of idiopathic hypereosinophilic syndrome to treatment with imatinib mesylate","volume":"26","author":"Ault","year":"2002","journal-title":"Leukemia Research"},{"issue":"September (5)","key":"10.1016\/j.leukres.2008.10.004_bib16","first-page":"9","article-title":"Case report: rapid and complete control of idiopathic hypereosinophilia with imatinib mesylate","volume":"3","author":"Schaller","year":"2001","journal-title":"MedGenMed"},{"issue":"September (9)","key":"10.1016\/j.leukres.2008.10.004_bib17","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.3324\/haematol.11420","article-title":"The efficacy of imatinib mesylate in patients with FIP1L1\u2013PDGFRalpha-positive hypereosinophilic syndrome Results of a multicenter prospective study","volume":"92","author":"Baccarani","year":"2007","journal-title":"Haematologica"},{"issue":"June (12)","key":"10.1016\/j.leukres.2008.10.004_bib18","doi-asserted-by":"crossref","first-page":"4714","DOI":"10.1182\/blood-2003-01-0081","article-title":"Efficacy of imatinib mesylate in the treatment of idiopathic hypereosinophilic syndrome","volume":"101","author":"Cortes","year":"2003","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.leukres.2008.10.004_bib19","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1111\/j.1600-0609.2006.00652.x","article-title":"The results of imatinib therapy for patients with primary eosinophilic disorders","volume":"76","author":"Helbig","year":"2006","journal-title":"European Journal of Haematology"},{"issue":"January (2)","key":"10.1016\/j.leukres.2008.10.004_bib20","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1182\/blood-2003-08-2798","article-title":"Molecular remission and reversal of myelofibrosis in response to imatinib mesylate treatment in patients with the myeloproliferative variant of hypereosinophilic syndrome","volume":"103","author":"Klion","year":"2004","journal-title":"Blood"},{"issue":"May (5)","key":"10.1016\/j.leukres.2008.10.004_bib21","first-page":"596","article-title":"The hypereosinophilic syndrome: fluorescence in situ hybridization detects the del(4)(q12)-FIP1L1\/PDGFRA but not genomic rearrangements of other tyrosine kinases","volume":"90","author":"La Starza","year":"2005","journal-title":"Haematologica"},{"issue":"January (1)","key":"10.1016\/j.leukres.2008.10.004_bib22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00277-005-1084-7","article-title":"Imatinib mesylate as a novel treatment option for hypereosinophilic syndrome: two case reports and a comprehensive review of the literature","volume":"85","author":"Muller","year":"2006","journal-title":"Annals of Hematology"},{"issue":"November (10)","key":"10.1016\/j.leukres.2008.10.004_bib23","doi-asserted-by":"crossref","first-page":"3038","DOI":"10.1182\/blood-2004-03-0787","article-title":"FIP1L1\u2013PDGFRA fusion: prevalence and clinicopathologic correlates in 89 consecutive patients with moderate to severe eosinophilia","volume":"104","author":"Pardanani","year":"2004","journal-title":"Blood"},{"issue":"May (5)","key":"10.1016\/j.leukres.2008.10.004_bib24","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1038\/sj.leu.2403722","article-title":"Molecular characterization of the idiopathic hypereosinophilic syndrome (HES) in 35 French patients with normal conventional cytogenetics","volume":"19","author":"Roche-Lestienne","year":"2005","journal-title":"Leukemia"},{"issue":"August (8)","key":"10.1016\/j.leukres.2008.10.004_bib25","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/j.leukres.2005.11.011","article-title":"FIP1L1\u2013PDGFRA in eosinophilic disorders: prevalence in routine clinical practice, long-term experience with imatinib therapy, and a critical review of the literature","volume":"30","author":"Pardanani","year":"2006","journal-title":"Leukemia Research"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212608004645?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212608004645?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,5,10]],"date-time":"2020-05-10T08:28:27Z","timestamp":1589099307000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212608004645"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,6]]},"references-count":25,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2009,6]]}},"alternative-id":["S0145212608004645"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2008.10.004","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2009,6]]}}}